Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

NCT05082610 is registered in ClinicalTrials.gov with Hummingbird Bioscience as lead sponsor.

NCT NCT05082610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Lead sponsor
Hummingbird Bioscience
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2022
Completion date
December 3, 2024
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, malignant neoplasm, metastatic cancer, nonsmall cell lung cancer, triple negative breast cancer, tumor, solid